Related Experiment Video
Updated: Mar 21, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence
Livia Brusa1, Carla Piano2,3, Elias Paolo Casula4,5
1UOC Neurologia, Movement Disorder Clinic, Ospedale S. Eugenio, Rome, Italy.
Background:
Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease (PD), highly impacting on quality-of-life and health-related costs.
Objectives:
Aim of our real-world study was to evaluate the impact of Foslevodopa/Foscarbidopa (LDp/CDp) subcutaneous infusion (CSCI) on nocturia in a group of advanced PD patients.
Methods:
Seventy-eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale (IPSS) and Nocturia Quality of Life (NQoL) questionnaire were administrated before starting LDp/CDp CSCI and after three months of infusion.
Results:
In this cohort, LDp/CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS-UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post-pre changes of IPSS and LEED showed a negative correlation.
Conclusions:
This study supports the utility of the overnight dopaminergic stimulation with LDp/CDp CSCI in controlling overactive bladder.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Drug Dosing: Geriatric Patients
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Oral Drug Delivery Systems: Continuous-Release Systems
